Earnings Feed
Start Free
First Tracks Biotherapeutics, Inc.·4

Apr 22, 4:05 PM ET

Jain Rita 4

Research Summary

AI-generated summary

Updated

First Tracks (TRAX) Director Rita Jain Receives 68,465 Awards

What Happened

  • Rita Jain, a director of First Tracks Biotherapeutics, acquired a total of 68,465 derivative awards on April 20, 2026. The filing lists eight grant entries (10,600; 8,015; 16,510; 16,510; 5,500; 1,300; 6,030; 4,000) at $0.00 per award (reported as type A — award/grant). These awards represent a mix of stock options and restricted stock units (RSUs) that were allocated in connection with First Tracks’ spin-off from AnaptysBio.
  • No cash was paid on acquisition (grants at $0). This is not a sale; it’s a distribution/award tied to the corporate separation and associated adjustments of pre-existing AnaptysBio awards.

Key Details

  • Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely).
  • Price: $0.00 per award; Total awards: 68,465 derivative securities.
  • Shares owned after transaction: not specified in the provided filing details.
  • Transaction code: A = Award/Grant (derivative securities: options and RSUs).
  • Notable footnotes:
    • Spin-off-related distribution from AnaptysBio (F1, F2, F6): pre-existing AnaptysBio options/RSUs were adjusted pro rata into First Tracks awards under the Separation Agreement.
    • Vesting/exercise specifics: some options are fully vested and exercisable (F3); others vest monthly starting Feb 6, 2026 (1/12 monthly) (F4); RSUs have varying schedules — 33.33% annual tranches through June 15, 2026 (F7), or cliff vesting at the Issuer’s 2026 or 2027 annual meetings (F8, F9). Each RSU represents a contingent right to one share upon settlement for no consideration (F5).
  • Filing timeliness: filed within the normal Form 4 reporting window (no late-filing indication).

Context

  • These awards result from corporate reorganization (spin-off) and the adjustment of prior AnaptysBio equity awards, rather than a market purchase or sale. That means they primarily reflect corporate mechanics and contractual vesting, not a direct insider market signal.
  • For retail investors: focus on vesting and potential dilution — some awards are already vested or become exercisable soon, while others remain subject to future service-based vesting.